Cheers Oilandgasman,
Amyndas has AMY-101, a C3 complement inhibitor and has orphan drug designation for a very rare condition called C3 glomerulopathy. Although, this condition does result in proteinuria (as do all diseases of the kidney that affect the glomerulus), this is a very different disease to FSGS and CKD nephropathy in general. The mechanism is also very different. So in summary- AMY-101 is playing in a different paddock to DMX-200- not in real competition.
Dimerix vs Amyndas, page-2
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $223.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $758.5K | 1.897M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20986 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 110235 | 2 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |